Dr. Alanee graduated cum laude from the College of the Medicine University of Baghdad and completed a fellowship in Urologic Oncology at the Memorial Sloan-Kettering Cancer Center in New York, New York. He has trained nationally and internationally on treating problems of the urinary system. Dr. Alanee previously served as the director of urologic oncology at Southern Illinois University and was the director of bladder cancer treatment and clinical trials program at Henry Ford Health System. While at Henry Ford Health System, he performed many robotic-assisted surgical firsts including the first intracorporeal urinary diversion after cystectomy for bladder cancer. His research interests include disparities in the delivery of healthcare, genetic bases of genitourinary cancer, immunotherapy of bladder cancer, and developing biomarkers for bladder and prostate cancer.
Current role
Scientific Advisor And Co-founder at Transformative
Managing Partner & Senior Scientific Advisor at Brookline Capital Markets
Chair of the Scientific Advisory Board at Therini Bio, Inc.
Scientific Advisor at zPREDICTA
Co-Founder and Scientific Advisor at Amorphology, Inc
Access the worlds's biggest network of public org charts
Learn more